Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects

[Background] Maraviroc is the first antiretroviral (ART) drug to target a human protein, the CCR5 coreceptor; however, the mechanisms of maraviroc-associated immunomodulation in human immunodeficiency virus (HIV)–infected subjects remain to be elucidated. Regulatory T cells (Tregs) play a key role i...

Descripción completa

Detalles Bibliográficos
Autores: Pozo-Balado, Maria del Mar del, Martínez Bonet, Marta, Rosado-Sánchez, Isaac, Ruiz-Mateos, Ezequiel, Méndez-Lagares, Gema, Rodríguez-Méndez, M. del Mar, Vidal, Francisco, Muñoz-Fernández, María Ángeles, Pacheco, Yolanda M., Leal, Manuel
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2014
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/389537
Acceso en línea:http://hdl.handle.net/10261/389537
https://api.elsevier.com/content/abstract/scopus_id/84907338624
Access Level:acceso abierto
Palabra clave:Regulatory T cells (Tregs)
ART naives
HIV
Maraviroc
Descripción
Sumario:[Background] Maraviroc is the first antiretroviral (ART) drug to target a human protein, the CCR5 coreceptor; however, the mechanisms of maraviroc-associated immunomodulation in human immunodeficiency virus (HIV)–infected subjects remain to be elucidated. Regulatory T cells (Tregs) play a key role in HIV-associated immunopathology and are susceptible to maraviroc-mediated CCR5 blockade. Our aim was to evaluate the effect of maraviroc on Tregs.

Similares en LA Referencia